Study of Weight Loss Using Gastric Stimulation in Obese Patients With Type 2 Diabetes
NCT ID: NCT00200018
Last Updated: 2009-02-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
46 participants
INTERVENTIONAL
2005-06-30
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Determine Tolerability to Glucagon Infusion in Obese Subjects
NCT02817659
Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Healthy Subjects
NCT01454973
Facilitated Release of Endogenous Enterokines
NCT04215328
Amylin and Glucagon-Like Peptide-1 (GLP-1): Influence on Gastric Emptying, Appetite and Food Intake in Humans
NCT00876213
A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus
NCT07313813
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Enterra Therapy System (H9900014)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willing to make behavior and lifestyle modifications
* No previous bariatric surgery (gastric bypass, gastric banding)
* Meet additional study criteria
Exclusion Criteria
* Prior GI surgery for morbid obesity or any gastric surgery for conditions other than obesity or diabetes
* Severe congestive heart failure
* Any underlying illness other than diabetes or obesity that affects gastrointestinal motility
* Currently taking medications for weight loss
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MedtronicNeuro
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Medtronic Neuromodulation
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ASSIST Team
Role: STUDY_CHAIR
Medtronic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
La Jolla, California, United States
Eagan, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1163-85585
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.